0001104659-21-076496.txt : 20210603
0001104659-21-076496.hdr.sgml : 20210603
20210603175536
ACCESSION NUMBER: 0001104659-21-076496
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210601
FILED AS OF DATE: 20210603
DATE AS OF CHANGE: 20210603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham G. Walmsley
CENTRAL INDEX KEY: 0001777517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 21993897
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 415-801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
tm2118278-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-01
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001777517
Graham G. Walmsley
C/O AKERO THERAPEUTICS, INC.,
601 GATEWAY BLVD, SUITE 350
SOUTH SAN FRANCISCO,
CA
94080
1
0
0
0
Stock Option (Right to Buy)
26.32
2021-06-01
4
A
0
13000
0
A
2031-05-31
Common Stock
13000
13000
D
Stock Option (Right to Buy)
26.32
2021-06-01
5
G
0
E
13000
0
D
2031-05-31
Common Stock
13000
0
D
Stock Option (Right to Buy)
26.32
2031-05-31
Common Stock
13000
13000
I
See footnote
Stock Option (Right to Buy)
19.97
2021-06-01
5
G
0
E
23832
0
D
2029-11-07
Common Stock
23832
0
D
Stock Option (Right to Buy)
19.97
2029-11-07
Common Stock
23832
23832
I
See footnote
Stock Option (Right to Buy)
25.2
2021-06-01
5
G
0
E
13000
0
D
2030-05-31
Common Stock
13000
0
D
Stock Option (Right to Buy)
25.2
2030-05-31
Common Stock
13000
13000
I
See footnote
This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.
On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member.
This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019.
On June 1, 2021, the reporting person transferred 23,832 options to an entity of which the reporting person is the sole member.
This option is fully vested.
On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member.
/s/ Jonathan Young, attorney-in-fact
2021-06-03